Navigation Links
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
Date:6/24/2009

PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822.

Oxford, UK (PRWEB) June 24, 2009 -- PharmaVentures Ltd, announced today that it provided the Helsinn Group with the transaction advisory support for the successful sale of Helsinn Chemicals Ireland Ltd to the Medinco C.F.M. Group, which was announced on Monday. Full details of this transaction can be found at http://www.prnewswire.co.uk/cgi/news/release?id=259822 .

Dr Fintan Walton, CEO, PharmaVentures commented, "PharmaVentures are delighted to have supported Helsinn in the strategic divestment of its pharmaceutical API manufacturing business. This success was achieved despite the current difficult economic environment and demonstrates why we are recognised as leaders in deal making. It also helps ensure an ongoing future for the Helsinn Chemicals Ireland business and its employees under the new ownership of the Medinco C.F.M. Group."

Please contact:

Dr Fintan Walton, CEO
PharmaVentures Ltd
+44 (0) 1865 784 187

About PharmaVentures Ltd
PharmaVentures (www.pharmaventures.com) assists pharmaceutical and biotechnology companies across the world in all aspects of deal making. The Company's core business is the provision of tailored advisory and transaction services to the Life Science industry, with additional deal making support provided through the PharmaDeals® range of intelligence products which include analysis tools and reports. An innovative business, PharmaVentures additionally provides industry insight, business reviews and deal making trends through the world's first online pharmaceutical television show www.pharmatelevision.com. Now in its 16th year PharmaVentures is based in Oxford, UK, employs over 50 people mostly educated to PhD or above, and has increased its turnover five fold with 80% of revenues from outside the UK. With offices in the USA and Australia, the Company works for a variety of clients from start-ups to global corporate pharmaceutical companies.

For further information about PharmaVentures Ltd please contact:
Lisa Holloway
Marketing
+44 (0) 1865 784 177

###

Read the full story at http://www.prweb.com/releases/2009/06/prweb2572184.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
2. Online Career Site Assists Academia in Its Reach
3. Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
4. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
5. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
6. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
7. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
8. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
9. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
10. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
11. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... FRANCISCO , June 16, 2016 ... size is expected to reach USD 1.83 ... by Grand View Research, Inc. Technological proliferation and ... banking applications are expected to drive the market ... ) , The development of advanced ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):